Carboplatin/Paclitaxel

DRUG7 trials

Conditions

Advanced Epithelial Ovarian CancerEndometrial CancerEsophageal Squamous Cell CarcinomaFirst-line Advanced NSCLC PatientsLocally Advanced Penile CarcinomaMale Urogenital DiseasesMelanomaNon-small Cell Lung Cancer

Early Phase 1

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

NCT03940001

Zhejiang Cancer HospitalEsophageal Squamous Cell Carcinoma

Start: 2019-05-01End: 2022-05-01Target: 20Updated: 2019-09-09

Phase 1

Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer

CompletedNCT05963334

Cairo UniversityAdvanced Epithelial Ovarian Cancer

Start: 2015-01-01End: 2023-06-06Updated: 2023-07-27

Phase 2

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

CompletedNCT01367002

Yale UniversityEndometrial Cancer

Start: 2011-06-30End: 2022-06-30Updated: 2023-05-17

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

RecruitingNCT05061550

AstraZenecaNon-small Cell Lung Cancer

Start: 2022-04-14End: 2030-05-28Target: 630Updated: 2026-03-11

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

RecruitingNCT06353906

The Netherlands Cancer InstituteLocally Advanced Penile Carcinoma, Male Urogenital Diseases, Penile Cancer +3

Start: 2024-08-13End: 2028-01-14Target: 27Updated: 2025-12-08

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

RecruitingNCT07171606

Shenyang Sunshine Pharmaceutical Co., LTD.First-line Advanced NSCLC Patients

Start: 2025-10-24End: 2027-08-31Target: 240Updated: 2025-12-18

Phase 3

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

CompletedNCT00111007

BayerMelanoma

Start: 2005-05-31End: 2009-01-31Updated: 2014-10-31

2026-01-20

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

2025-05-316 citations

Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.

Journal of Clinical Oncology2025-05-28

Comparison of Endometrial Serous and Gastric HER2 Immunohistochemistry Scoring Schemes in Endometrial Carcinomas With Aberrant p53 Expression: Reproducibility and In Situ Hybridization Correlation

International Journal of Gynecological Pathology2025-05-192 citations

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

Future Oncology2024-07-1830 citations

Safety and short-term outcomes of esophagectomy after neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell cancer: analysis of two phase-II clinical trials.

2024-06-273 citations

Safety and feasibility of esophagectomy following neoadjuvant immunotherapy combined with chemotherapy or chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: Analysis of two phase 2 clinical trials.

Journal of Clinical Oncology2024-06-012 citations

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

2023-12-1929 citations

HER2 Status Assessment in Endometrial Serous Carcinoma: Comparative Analysis of Two Proposed Testing and Interpretation Algorithms

International Journal of Gynecological Pathology2023-06-0911 citations

NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-0110 citations

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Cancer Immunology Immunotherapy2023-04-0589 citations

Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC)

Cancer Research2022-06-153 citations

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Clinical Cancer Research2020-06-29292 citations